13.67
price down icon4.47%   -0.64
after-market Handel nachbörslich: 13.87 0.20 +1.46%
loading

Denali Therapeutics Inc Aktie (DNLI) Neueste Nachrichten

pulisher
Jul 24, 2025

Will Denali Therapeutics Inc. stock benefit from interest rate changesFree Investment Community - jammulinksnews.com

Jul 24, 2025
pulisher
Jul 23, 2025

What analysts say about Denali Therapeutics Inc. stockOutstanding capital growth - Autocar Professional

Jul 23, 2025
pulisher
Jul 23, 2025

What drives Denali Therapeutics Inc. stock priceFree Technical Analysis Support - Autocar Professional

Jul 23, 2025
pulisher
Jul 23, 2025

Is Denali Therapeutics Inc. a good long term investmentOutperformance with explosive growth - jammulinksnews.com

Jul 23, 2025
pulisher
Jul 23, 2025

Denali Therapeutics Inc. Stock Analysis and ForecastRapidly expanding wealth - jammulinksnews.com

Jul 23, 2025
pulisher
Jul 19, 2025

What makes Denali Therapeutics Inc. stock price move sharply3x Return Stock Radar - beatles.ru

Jul 19, 2025
pulisher
Jul 19, 2025

BTIG Reiterates a Buy Rating on Denali Therapeutics (DNLI) With a $32 Price Target - MSN

Jul 19, 2025
pulisher
Jul 16, 2025

12 Oversold NASDAQ Stocks to Buy Now - Insider Monkey

Jul 16, 2025
pulisher
Jul 15, 2025

When (DNLI) Moves Investors should Listen - news.stocktradersdaily.com

Jul 15, 2025
pulisher
Jul 11, 2025

Denali Therapeutics' Insider Sale: Routine Diversification or a Cause for Concern? - AInvest

Jul 11, 2025
pulisher
Jul 09, 2025

DNLI SEC FilingsDenali Therapeut 10-K, 10-Q, 8-K Forms - Stock Titan

Jul 09, 2025
pulisher
Jul 08, 2025

FDA accepts priority review for Denali’s Hunter syndrome therapy By Investing.com - Investing.com South Africa

Jul 08, 2025
pulisher
Jul 08, 2025

FDA accepts priority review for Denali’s Hunter syndrome therapy - Investing.com Australia

Jul 08, 2025
pulisher
Jul 08, 2025

Stifel Nicolaus Reaffirms Their Buy Rating on Denali Therapeutics (DNLI) - The Globe and Mail

Jul 08, 2025
pulisher
Jul 07, 2025

Denali Therapeutics stock gains as FDA grants priority review for Hunter syndrome drug - Investing.com Nigeria

Jul 07, 2025
pulisher
Jul 07, 2025

Denali Therapeutics stock gains as FDA grants priority review for Hunter syndrome drug By Investing.com - Investing.com South Africa

Jul 07, 2025
pulisher
Jul 07, 2025

Denali Therapeutics Announces FDA Acceptance and Priority - GlobeNewswire

Jul 07, 2025
pulisher
Jul 07, 2025

Factor Thisâ„¢ Energy Understood. All Factored In. - FinancialContent

Jul 07, 2025
pulisher
Jul 07, 2025

First Brain-Penetrating Hunter Syndrome Treatment in 20 Years Gets FDA Priority Review - Stock Titan

Jul 07, 2025
pulisher
Jun 30, 2025

Denali Therapeutics Insiders Sell US$1.9m Of Stock, Possibly Signalling Caution - simplywall.st

Jun 30, 2025
pulisher
Jun 26, 2025

Denali Therapeutics: Navigating Through Recent Setbacks (NASDAQ:DNLI) - Seeking Alpha

Jun 26, 2025
pulisher
Jun 24, 2025

(DNLI) Proactive Strategies - news.stocktradersdaily.com

Jun 24, 2025
pulisher
Jun 23, 2025

Denali Therapeutics stock poised for catalyst as FDA decision nears By Investing.com - Investing.com South Africa

Jun 23, 2025
pulisher
Jun 13, 2025

(DNLI) Investment Analysis - news.stocktradersdaily.com

Jun 13, 2025
pulisher
Jun 10, 2025

Transcript : Denali Therapeutics Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-10-2025 01 - MarketScreener

Jun 10, 2025
pulisher
Jun 09, 2025

Denali Therapeutics Inc. (NASDAQ:DNLI) Receives Consensus Recommendation of “Buy” from Brokerages - Defense World

Jun 09, 2025
pulisher
Jun 06, 2025

Ameriprise Financial Inc. Has $341,000 Stock Holdings in Denali Therapeutics Inc. (NASDAQ:DNLI) - Defense World

Jun 06, 2025
pulisher
Jun 06, 2025

15,100 Shares in Denali Therapeutics Inc. (NASDAQ:DNLI) Acquired by Two Sigma Advisers LP - Defense World

Jun 06, 2025
pulisher
Jun 05, 2025

Why Is Denali Therapeutics (DNLI) Up 0.7% Since Last Earnings Report? - Yahoo Finance

Jun 05, 2025
pulisher
Jun 03, 2025

Denali Therapeutics Enters Registration Rights Agreement - TipRanks

Jun 03, 2025
$23.40
price down icon 0.97%
$36.67
price up icon 0.22%
$103.95
price up icon 0.42%
$28.67
price up icon 3.99%
$115.31
price up icon 0.65%
biotechnology ONC
$291.47
price down icon 1.68%
Kapitalisierung:     |  Volumen (24h):